)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sinopharm Group
Sinopharm Group (1099) investor relations material
Sinopharm Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary26 Oct, 2026
Executive summary
9M 2026 revenue was RMB427.61bn and net profit RMB8.08bn; revenue and net profit were below 9M 2025 levels.
Net profit attributable to equity holders of the parent was RMB5.31bn, compared with RMB5.31bn in 9M 2025.
Financial highlights
Operating profit was RMB10.78bn vs RMB10.87bn; total profit was RMB10.80bn vs RMB10.88bn in 9M 2025.
Operating revenue was RMB427.61bn vs RMB431.48bn; operating cost was RMB397.73bn vs RMB400.21bn.
Net profit was RMB8.08bn vs RMB8.10bn; parent-attributable net profit was RMB5.31bn vs RMB5.31bn.
Operating cash outflow was RMB23.93bn, improving from RMB39.08bn in 9M 2025.
Key financial ratios and metrics
Basic and diluted EPS were both RMB1.70 for 9M 2026 and 9M 2025.
Total assets were RMB407.87bn at 30 Sep 2026 vs RMB390.21bn at 31 Dec 2025; total liabilities were RMB268.60bn vs RMB255.86bn.
Consolidated equity was RMB139.27bn at 30 Sep 2026 vs RMB134.35bn at 31 Dec 2025.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sinopharm Group
- Revenue grew 8.05%, with lower expense ratios but weaker operating cash flow.1099
Q4 2023 - Revenue and profit declined, but retail pharmacy grew and cost controls improved margins.1099Q2 2026
- Revenue rose 1.23% but operating profit fell 20.41% year-over-year for Q1 2026.1099Q1 2026
- Net profit grew 3.94% to RMB 10.83 billion despite a 1.6% revenue decline, led by retail pharmacy gains.1099Q4 2025
- Revenue and profit fell, but operating cash flow and balance sheet improved.1099Q3 2025
- Revenue and profit declined, but retail pharmacy grew and expense ratios improved.1099Q2 2025
- Revenue and net profit declined year-over-year, with negative operating cash flow and rising liabilities.1099Q3 2024
- Revenue and profit fell, but digital transformation and liquidity remained strong.1099Q2 2024
- Net profit fell 22.14% as revenue declined and margin pressure persisted.1099Q4 2024
Next Sinopharm Group earnings date
Q4 202625 Mar, 2027
Sinopharm Group
Next Sinopharm Group earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sinopharm Group Co. Ltd. is a healthcare company specializing in the distribution and supply of pharmaceutical products, medical devices, and healthcare services. The company operates an extensive distribution network, providing a wide range of medicines, vaccines, and diagnostic products to hospitals, pharmacies, and other healthcare institutions. Sinopharm is also involved in retail pharmacy operations and healthcare logistics services, supporting the medical and pharmaceutical sectors. The company is headquartered in Shanghai, China, and its shares are listed on the SEHK.